SEPTEMBER 12, 2019
Member/Center Highlights
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
Swallowable Device to Detect Pre-Cancerous Barrett's Esophagus Receives FDA 510(k) Clearance
Investigators at Case Western Reserve University School of Medicine, the Case Comprehensive Cancer Center and University Hospitals Cleveland Medical Center developed the test for early detection of Barrett’s esophagus that offers promise for preventing deaths from esophageal adenocarcinoma.

The test involves a novel swallowable balloon device that samples the esophagus and a DNA assay that detects Barrett’s esophagus and esophageal cancers. In a major step to bringing this technology forward to patients, the balloon device has just received 510K clearance from the U.S. Food and Drug Administration (FDA) for clinical use. The now FDA-cleared device is being manufactured by Lucid Diagnostics and marketed under the tradename EsoCheck.
The device was developed by School of Medicine faculty and University Hospitals physicians Amitabh Chak, MD, Joseph Willis, MD, and Sanford Markowitz, MD, PhD , all of whom are members of the Case Comprehensive Cancer Center.
The American Society for Radiation Oncology Annual Meeting begins this Sunday, September 15!
cancer research institute logo
September is Childhood Cancer Awareness Month. Check out the Cancer Research Institute's informational page on immunotherapy for children and adolescents with cancer, reviewed by Alex Huang, MD, PhD. Dr. Huang is a pediatric hematologist oncologist at University Hospitals Rainbow Babies and Children's Hospital, professor of pediatrics and associate professor of pathology at the School of Medicine, member of the Hematopoietic and Immune Cancer Biology Program at the Case CCC and co-chair of the upcoming Innovators in AYA Cancer Symposium.
News from our Clinical Partners
What's Coming Up
Mark Your Calendar
Returns Tomorrow: Cancer Center Seminar Series
September 13, 12p
WRB Auditorium

Our interdisciplinary seminar series addresses cutting-edge clinical, translational, and basic research topics in cancer. Held weekly on Fridays at 12 pm in the Wolstein Research Building Auditorium, 1-413, attendees are able to interact with our speakers and receive CME credit for the educational activity.

Our series returns Friday, September 13, 2019 with Abhishek Chakraborty, PhD presenting, "Exploiting Dioxygenase Dysfunction to Target Cancer" on behalf of the GU Malignancies Program. Dr. Chakraborty is Assistant Staff, GU Malignancies Research Center at Cleveland Clinic Lerner Research Institute.

We look forward to seeing you each week as the academic year begins again.
Cancer Center Seminar Series
September 20, 12p
Alternate Location: BRB Auditorium 105

Next week's Cancer Center Seminar will take place in the Biomedical Research Building Auditorium, 105 at 12 pm and feature Yogen Saunthararajah, MD. He will present, "Non-Cytotoxic . Drugs to Terminate Cancer but not Normal Self-Replication."

Dr. Saunthararajah is a staff physician at Cleveland Clinic, professor of medicine at Case Western Reserve University School of Medicine and Co-Leader of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center. 
Racial Equity Institute (REI) Groundwater Training
September 18, 5p-8p
Wolstein Research Building
Researchers and clinicians are invited to join the Case CCC Office of Cancer Disparities Research and the Prevention Research Center for Healthy Neighborhoods (PRCHN) for a learning journey to increase shared understanding of racial inequities that impact health, and to discuss strategies to promote a more equitable society.

  • Inform your catchment area, disparities and/or community-based research
  • Learn how structures (e.g., healthcare, education) lead to inequities
  • Build better community-academic collaborations
  • Improve patient and community engagement
  • Be a part of our institutional transformation

This training is free to attend, but registration is required. Dinner will be provided. Use password CWRU to register below.
NCI logo
Symposium on Personal Control of Genomic Data for Research
September 26-27
Bethesda, MD

The National Cancer Institute is hosting a symposium to explore the impact of personal control of genomic data sharing to research, clinical care, and patient well-being and engagement.

Registration is now open for the event, which will be held in the Masur Auditorium at the Clinical Center on the NIH campus in Bethesda, MD from 8a-5p September 26 and 9a-12p September 27.

The NCI is also accepting abstract submissions for poster presentations at the symposium until Friday, September 20.

Topics will include:
  • Motivations for and perceptions of participants controlling their own data
  • Facilitating personal control of data sharing
  • Risks and benefits to participants in their communities
  • The role of individuals who wish to share their data in clinical practice and healthcare.

You can also follow the symposium and join the conversation on Twitter with #NCIParticipantShareData19.
Women's Cancers Initiative Mini-Retreat
September 28, 8a-1p
WRB Auditorium

Members: as the Case Comprehensive Cancer Center builds the Women's Cancers Initiative, a mini-retreat will be held Saturday, September 28 to identify investigators, projects and general themes of research strengths and interests.

Our goal is to be as comprehensive as possible to ensure that all aspects of Women's Cancers research being conducted in Cleveland are represented at the retreat and in the initiative. Additional information regarding the retreat structure will be available soon.
Early Bird Registration Ending: Artificial Intelligence in Oncology Symposium
October 24, 2019
Tinkham Veale University Center

The Case Comprehensive Cancer Center and Center for Computational Imaging and Personalized Diagnostics at Case Western Reserve University (CWRU) will host the inaugural  Artificial Intelligence in Oncology Symposium : Advancements in Policy at CWRU on Thursday, October 24, 2019.

The symposium will bring together experts in AI and machine learning as well as clinical, industry and federal agency experts in pathology, radiology, oncology and immuno-oncology to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI.

Symposium Highlights:
  • Focused panel discussions
  • Networking opportunities
  • Exhibitions available throughout the day

  • Sohrab Shah, PhD, Chief, Computational Oncology, Memorial Sloan Kettering Cancer Center

Discounted early bird registration ENDS this Sunday, September 15. Seats are filling quickly, so don't wait! A discount for students and trainees who wish to attend is available. We look forward to seeing you in October!
Early Bird Registration and Call for Abstracts: Innovators in AYA Cancer
November 14-15, 2019
Tinkham Veale University Center

The Angie Fowler Adolescent and Young Adult (AYA) Cancer Research Initiative of the Case Comprehensive Cancer Center invites you to attend Innovators in AYA Cancer: Driving Science and Policy toward a Brighter Future for Teens and Young Adults with Cancer this November at Case Western Reserve University.

Call for Abstracts
The Symposium will feature a poster session and Rising Star oral presentations. All students, postdocs, residents, fellows and faculty conducting research in AYA cancer are invited to submit abstracts. Monetary prizes will be awarded. Abstracts must be submitted electronically by Friday, October 18, 2019 at 5pm ET. Learn more>

Be sure to register by October 18, 2019 to secure our discounted early bird registration . A discount for students and trainees who wish to attend is available. We look forward to seeing you in November!
Save the Date: 4th Annual Cancer Disparities Symposium
March 6, 2020
Tinkham Veale University Center

The Case Comprehensive Cancer Center Office of Cancer Disparities Research will present the   4th Annual Cancer Disparities Symposium : Cultivating Science and Community Engagement to Address Cancer Health Disparities on March 6, 2020. 

The symposium will feature keynote presentations by renowned disparities
researchers and community leaders, a poster session highlighting academic research and community programs, networking session and an all-attendee forum.

Call for Abstracts
The   4th Annual Cancer Disparities Symposium is a premier event for presenting cutting-edge cancer disparities science and related community programs and services. The Office of Cancer Disparities Research will divide abstracts into two tracks:   Scientific Research   and   Community Programs and Services . Scientific Research abstracts are encouraged from multidisciplinary researchers that are focused on various aspects of health disparities and/or community-focused science. Community programs and service abstracts are encouraged from organizations that provide programs and services that benefit the community. Meritorious abstracts will be selected for oral presentation.  Abstracts must be submitted electronically by 5 pm EST on Tuesday, December 3, 2019.   Learn more>

Further registration details will be released soon!
Additional Upcoming Events
MetroHealth Cancer Care Symposium
September 20, 1-5p
MetroHealth Medical Center, R170
Cleveland Clinic Children's Pediatric Cancer Survivorship Symposium
September 28, 2019, 8a-3:30p
Cleveland Clinic Main Campus
Cleveland Clinic Colorectal Oncology Conference
October 18-19, 2019, 8a-3:30p
Naples, FL
Discounted registration ends today!
Cleveland Clinic Breast Cancer Update: From Detection Through Treatment to Survivorship
November 13, 2019
Independence, OH
Funding Opportunities
Deadlines vary by award

The Melanoma Research Alliance (MRA) has announced a Request for Proposals (RFP) soliciting high-impact pre-clinical, translational, and early clinical research from scientists and clinicians around the world. The RFP calls for ideas that have the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment.

The below opportunities are detailed in the MRA 2019-2020 Request for Proposals.

Melanoma Metastasis Team Science Award, jointly sponsored by the Rising Tide Foundation for Clinical Cancer Research
LOI deadline: October 7, 2019

Acral Melanoma Team Science Award
LOI deadline: October 7, 2019

Melanoma Detection or Prevention Mid-Career Investigator Award, jointly sponsored with the Dermatology Foundation
Full proposal deadline: November 18, 2019

Radiation Oncology Young Investigator Award with ASTRO
Full proposal deadline: November 18, 2019

Immunotherapy Young Investigator Awards Supported by Bristol Myers Squibb
Full proposal deadline: November 18, 2019
LOI Deadline: October 8

Rally funds research in the following areas:
  • Childhood and adolescent cancers
  • Under-studied childhood and adolescent cancer types
  • Innovative approaches to childhood and adolescent cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals

  • Fellows, Research Scientists, Instructors and Professors with MD, PhD, or MD, PhD degrees may apply
  • PIs need not be US. citizens.
  • Lead research institutions do not need to be located in the US

Award Categories
All grants are for one or two years of support. At the end of each award, you may apply for additional funding the next grant cycle.
  • Fellowship Grants – funded up to $50,000 per year.
  • Young Investigator and Independent Investigator Research Grants – funded up to $50,000 per year.
  • Consortium Grants (three or more institutions collaborating on a grant-supported research project) – funded up to $100,000 per year.
Deadline: October 15

The Rivkin Center for Ovarian Cancer is accepting applications for a Bridge Funding Award based on scientific merit. Bridge Funding allows researchers to produce data needed to substantiate their proposal resubmission to federal funding agencies for a promising new research project.

The Rivkin Center Bridge Funding Award provides interim funding of up to $30,000 for six months to researchers who have submitted an R01, R21, K08, K23, or K99 proposal to the National Institutes of Health (NIH) or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer and who have not received, but were close to, a fundable score. With more data, ovarian cancer researchers stand a better chance of being successfully funded with a stronger, resubmitted proposal.

Investigator-initiated projects in all areas of ovarian cancer research are eligible. Special consideration will be given to research that has clinical applicability. Funds are for direct costs only. Applicants may budget for salary support, materials, supplies, consumables, and other expenses as justified.
Deadline: October 15

The Taub Foundation Grants Program for Myelodysplastic Syndromes (MDS) Research was created to support high-impact, innovative translational research to understand the underlying causes of MDS and to advance its treatment and prevention. The Program specifically focuses on MDS research, exclusive of AML and MPN. Studies focusing on molecular genetics, epigenetics, splicing factors, stem cells, the microenvironment and novel therapeutic targets relevant to MDS are encouraged.

Innovative studies with transformative potential to elucidate MDS etiology and to develop new treatments are particularly encouraged.

To promote the expansion of the MDS research field collaborative efforts and proposals from young investigators and those from non-MDS fields are encouraged to apply.

  • Independent investigators at all career stages working in non-profit, non-governmental academic, medical, or research institutions within the United States

Award Details
  • 3 year, $600,000 awards
  • Inclusive of 10% indirect costs
  • Collaborative efforts encouraged
In The News
Onc Live TV - Aug 16
Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, and professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses improving access to cancer therapy with biosimilars. Dr. Abraham is a member of the Developmental Therapeutics Program at the Case CCC.
Journal of Clinical Pathways - Sept 10
Faculty at the University Hospitals Seidman Cancer Center were interviewed regarding their unique positioning for cancer treatment in the greater Cleveland area and within the American Midwest. Among those interviewed was Theodoros Teknos, MD, president and scientific officer of University Hospitals Seidman Cancer Center, and deputy director for University Hospitals at the Case CCC.
From The NIH
Weekly NIH Funding Opportunities and Notices

Funding Opportunities
Deadlines: November 8, 2019, March 9, 2020, July 9, 2020, March 9, 2021, July 9, 2021

Deadlines: November 8, 2019, March 9, 2020, July 9, 2020, March 9, 2021, July 9, 2021

Deadlines: November 8, 2019, March 9, 2020, July 9, 2020, March 9, 2021, July 9, 2021

Deadlines: November 8, 2019, March 9, 2020, July 9, 2020, March 9, 2021, July 9, 2021

Deadlines: November 8, 2019, March 9, 2020, July 9, 2020, March 9, 2021, July 9, 2021

Deadlines: November 18, 2019; October 15, 2020; October 15, 2021

Standard Dates Apply

Deadlines: January 17, 2020; May 18, 2020; January 19, 2021; May 17, 2021; January 18, 2022, May 17, 2022
Have something to share?
Use the button to the right to submit all your news, events, announcements and communications requests to the Case CCC Marketing and Communications team!